Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Madurahydroxylactone, an Inhibitor of Staphylococcus aureus FtsZ from Nonomuraea sp. AN100570

  • Kim, Bo-Min (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Choi, Ha-Young (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Geon-Woo (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Zheng, Chang-Ji (Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, Yanbian University College of Pharmacy) ;
  • Kim, Young-Ho (Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, Yanbian University College of Pharmacy) ;
  • Kim, Won-Gon (Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology)
  • Received : 2017.08.18
  • Accepted : 2017.09.06
  • Published : 2017.11.28
Download PDF
⟨ Previous Next ⟩

Abstract

FtsZ, a bacterial cell-division protein, is an attractive antibacterial target. In the screening for an inhibitor of Staphylococcus aureus FtsZ, madurahydroxylactone (1) and its related derivatives 2-5 were isolated from Nonomuraea sp. AN100570. Compound 1 inhibited S. aureus FtsZ with an $IC_{50}$ of $53.4{\mu}M$ and showed potent antibacterial activity against S. aureus and MRSA with an MIC of $1{\mu}g/ml$, whereas 2-5 were weak or inactive. Importantly, 1 induced cell elongation in the cell division phenotype assay, whereas 2-5 did not. It indicates that 1 exhibits its potent antibacterial activity via inhibition of FtsZ, and the hydroxyl group and hydroxylactone ring of 1 are critical for the activity. Thus, madurahydroxylactone is a new type of inhibitor of FtsZ.

Keywords

References

  1. Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis 13: 1840-1846. https://doi.org/10.3201/eid1312.070629
  2. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide:causes, challenges and responses. Nat. Med. 10: S122-S129. https://doi.org/10.1038/nm1145
  3. Brown ED, Wright GD. 2016. Antibacterial drug discovery in the resistance era. Nature 529: 336-343. https://doi.org/10.1038/nature17042
  4. Butler MS, Cooper MA. 2012. Screening strategies to identify new antibiotics. Curr. Drug Targets 13: 373-387. https://doi.org/10.2174/138945012799424624
  5. Lock RL, Harry EJ. 2008. Cell-division inhibitors: new insights for future antibiotics. Nat. Rev. Drug Discov. 7: 324-338. https://doi.org/10.1038/nrd2510
  6. Vollmer W. 2006. The prokaryotic cytoskeleton: a putative target for inhibitors and antibiotics? Appl. Microbiol. Biotechnol. 73: 37-47. https://doi.org/10.1007/s00253-006-0586-0
  7. Kapoor S, Panda D. 2009. Targeting FtsZ for antibacterial therapy: a promising avenue. Expert Opin. Ther. Targets 13: 1037-1051. https://doi.org/10.1517/14728220903173257
  8. Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, et al. 2008. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321: 1673-1675. https://doi.org/10.1126/science.1159961
  9. Sun N, Chan FY, Lu YJ, Neves MA, Lui HK, Wang Y et al. 2014. Rational design of berberine-based FtsZ inhibitors with broad-spectrum antibacterial activity. PLoS One 9: e97514. https://doi.org/10.1371/journal.pone.0097514
  10. Wang J, Galgoci A, Kodali S, Herath KB, Jayasuriya H, Dorso K, et al. 2003. Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J. Biol. Chem 278: 44424-44428. https://doi.org/10.1074/jbc.M307625200
  11. Stokes NR, Sievers J, Barker S, Bennett JM, Brown DR, Collins I, et al. 2005. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem. 280: 39709-39715. https://doi.org/10.1074/jbc.M506741200
  12. Domadia PN, Bhunia A, Sivaraman J, Swarup S, Dasgupta D. 2008. Berberine targets assembly of Escherichia coli c ell division protein FtsZ. Biochemistry 47: 3225-3234. https://doi.org/10.1021/bi7018546
  13. Beuria TK, Santra MK, Panda D. 2005. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. Biochemistry 44: 16584-16593. https://doi.org/10.1021/bi050767+
  14. Park YS, Grove CI, Gonzalez-Lopez M, Urgaonkar S, Fettinger JC, Shaw JT. 2011. Synthesis of (-)-viriditoxin: a 6,6'-binaphthopyran-2-one that targets the bacterial cell division protein FtsZ. Angew. Chem. Int. Ed. Engl. 50: 3730-3733. https://doi.org/10.1002/anie.201007298
  15. Stokes NR, Baker N, Bennett JM, Berry J, Collins I, Czaplewski LG, et al. 2013. An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy. Antimicrob. Agents Chemother. 57: 317-325. https://doi.org/10.1128/AAC.01580-12
  16. Fleck WF, Strauss DG, Meyer J, Porstendorfer G. 1978. Fermentation, isolation, and biological activity of maduramycin:a new antibiotic from Actinomadura rubra. Z. Allg. Mikrobiol. 18: 389-398. https://doi.org/10.1002/jobm.3630180602
  17. Marchand C, Beutler JA, Wamiru A, Budihas S, Mollmann U, Heinisch L et al. 2008. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrob. Agents Chemother. 52:361-364. https://doi.org/10.1128/AAC.00883-07
  18. Heinisch L, Roemer E, Jutten P, Haas W, Werner W, Mollmann U. 1999. Semisynthetic derivatives of madura hydroxylactone and their antibacterial activities. J. Antibiot. (Tokyo) 52: 1029-1041. https://doi.org/10.7164/antibiotics.52.1029
  19. Strauss DG, Baum M, Fleck WF. 1986. Butylmaduramycin, a new antibiotic from Actinomadura rubra. J. Basic Microbiol. 26: 169-172. https://doi.org/10.1002/jobm.3620260307
  20. Zheng CJ, Sohn MJ, Kim WG. 2009. Vinaxanthone, a new FabI inhibitor from Penicillium sp. J. Antimicrob. Chemother. 63: 949-953. https://doi.org/10.1093/jac/dkp058

Cited by

  1. Dialogue between Staphylococcus aureus SA15 and Lactococcus garvieae strains experiencing oxidative stress vol.18, pp.None, 2018, https://doi.org/10.1186/s12866-018-1340-3
  2. The secondary metabolites of rare actinomycetes: chemistry and bioactivity vol.9, pp.38, 2019, https://doi.org/10.1039/c9ra03579f
  3. Moroccan actinobacteria with promising activity against toxic cyanobacteria Microcystis aeruginosa vol.28, pp.1, 2017, https://doi.org/10.1007/s11356-020-10439-2